radiosensitizes

By Targets:	Amyloid-β (1) Apoptosis (6) ATM/ATR (3) Bacterial (1) Biochemical Assay Reagents (1) Calcium Channel (1) DNA/RNA Synthesis (3) E1/E2/E3 Enzyme (4) EGFR (1) Endogenous Metabolite (3) Glutaminase (1) Glutathione S-transferase (1) HDAC (1) Isotope-Labeled Compounds (1) Mitochondrial Metabolism (1) Monocarboxylate Transporter (1) NF-κB (2) NO Synthase (1) Parasite (1) Phosphatase (1) PI3K (1) PPAR (1) PROTACs (1)
By Research Areas:	Cancer (23) Infection (1) Inflammation/Immunology (1) Neurological Disease (1)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-B0332

Menadione Maximum Cited Publications 14 Publications Verification Vitamin K3	Endogenous Metabolite	Others
Menadione is a naphthoquinone that is converted into active vitamin K2 in the body. Menadione is a potential anticancer agent and radiosensitizer .

HY-116972

Etanidazole

SR 2508
Others Cancer

Etanidazole (SR 2508), a 2-nitroimidazole compound, is a hypoxic radiosensitizer used in cancer diagnosis and chemotherapy research .
HY-123290

KCC009

Glutaminase Cancer

KCC009, a transglutaminase 2 (TG2) inhibitor, induces p53-independent radiosensitization .

Etanidazole SR 2508	Others	Cancer
Etanidazole (SR 2508), a 2-nitroimidazole compound, is a hypoxic radiosensitizer used in cancer diagnosis and chemotherapy research .

KCC009	Glutaminase	Cancer
KCC009, a transglutaminase 2 (TG2) inhibitor, induces p53-independent radiosensitization .

HY-117630

RB-6145	Others	Cancer
RB-6145 is an orally active pro-drug of the hypoxic cell radiosensitizer RSU 1069. RB-6145 acts a hypoxic cell radiosensitizer and cytotoxin but reduces systemic toxicity in mice .

HY-152147

SZUH280	PROTACs HDAC Apoptosis DNA/RNA Synthesis	Cancer
SZUH280 is a potent and selective PROTAC HDAC8 degrader with a DC₅₀ of 0.58 μM in A549 cells. SZUH280 induces cancer cell apoptosis. SZUH280 hampers DNA damage repair in cancer cells, promoting cellular radiosensitization .

HY-P3229

SN52 1 Publications Verification	NF-κB	Cancer
SN52 is a potent, competitive, and cell-permeable inhibitor of NF-κB2. SN52 is a variant of the SN50 peptide and inhibits the nuclear translocation of p52-RelB heterodimers. SN52 has a strong radiosensitization effect on prostate cancer cells. SN52 can be used for cancer research .

HY-112198

AZ31	ATM/ATR	Cancer
AZ31 is a a potent, highly selective, and orally active ATM inhibitor with an IC₅₀ of <1.2 nM for ATM enzyme, and an IC₅₀ of 46 nM for ATM in cell. AZ31 shows excellent selectivity over ATR (>500-fold) and excellent PIKK-family selectivity and pan-kinase selectivity. AZ31 is a potent radiosensitizer in vitro, it can be used for the research of cancer .

HY-103241

Ro 90-7501 1 Publications Verification	Amyloid-β ATM/ATR Phosphatase Apoptosis	Neurological Disease Cancer
Ro 90-7501 is an amyloid β₄₂ (Aβ₄₂) fibril assembly inhibitor that reduces Aβ₄₂-induced cytotoxicity (EC₅₀ of 2 μM). Ro 90-7501 inhibits ATM phosphorylation and DNA repair. RO 90-7501 selectively enhances toll-like receptor 3 (TLR3) and RIG-I-like receptor (RLR) ligand-induced IFN-β gene expression and antiviral response . Ro 90-7501 also inhibits protein phosphatase 5 (PP5) in a TPR-dependent manner . Ro 90-7501 has significant radiosensitizing effects on cervical cancer cells .

HY-162002

WSD0628

ATM/ATR Cancer

WSD0628 is a brain penetrant and potent ATM inhibitor with profound radiosensitizing effect .
HY-13742

Ropidoxuridine

IPdR
Others Cancer

Ropidoxuridine (IPdR) is a novel orally available, halogenated thymidine analog and is a potential radiosensitizer for use in human tumors.

WSD0628	ATM/ATR	Cancer
WSD0628 is a brain penetrant and potent ATM inhibitor with profound radiosensitizing effect .

Ropidoxuridine IPdR	Others	Cancer
Ropidoxuridine (IPdR) is a novel orally available, halogenated thymidine analog and is a potential radiosensitizer for use in human tumors.

HY-10082

Triapine 3 Publications Verification 3-AP; PAN-811; OCX191	DNA/RNA Synthesis	Cancer
Triapine (3-AP; PAN-811) is a potent inhibitor of the M2 subunit of ribonucleotide reductase (RR), and is a potent radiosensitizer.

HY-105061

Misonidazole Ro 7-0582; SR 1354	Bacterial Parasite	Infection Cancer
Misonidazole (Ro 7-0582; SR 1354) is a hypoxic tumor cell radiosensitizer . Misonidazole also has antimicrobial effects .

HY-N4164

Schinifoline	Apoptosis	Cancer
Schinifoline, a 4-quinolinone derivative isolated from Zanthoxylum schinifolium Sieb, improves radiosensitizing effect, and effects cell cycle and apoptotic-inducing effects in cancer .

HY-137552

MKI-1 MASTL Kinase Inhibitor-1	Others	Cancer
MKI-1, an inhibitor of MASTL (microtubule-associated serine/threonine kinase-like) with an IC₅₀ of 9.9 μM, exerts antitumor and radiosensitizer activities through PP2A activation in breast cancer .

HY-108692

Enterolactone	Apoptosis Endogenous Metabolite	Cancer
Enterolactone is a bioactive phenolic metabolite known as a mammalian lignan derived from dietary lignans. Enterolactone has estrogenic properties and anti-breast cancer activity . Enterolactone is a radiosensitizer for human breast cancer cell lines through impaired DNA repair and increased apoptosis .

HY-W076740

8-Bromoadenine 8-Bromo-9H-purin-6-amine	DNA/RNA Synthesis Biochemical Assay Reagents	Others
8-Bromoadenine (8-Bromo-9H-purin-6-amine) is a DNA radiosensitizer that inhibits DNA single-strand break repair in cells. 8-Bromoadenine is a brominated derivative of adenine, and radioactive adenine can be prepared by replacing bromine with deuterium .

HY-108692S

Enterolactone-d6	Isotope-Labeled Compounds Apoptosis Endogenous Metabolite	Cancer
Enterolactone-d₆ is the deuterium labeled Enterolactone. Enterolactone is a bioactive phenolic metabolite known as a mammalian lignan derived from dietary lignans. Enterolactone has estrogenic properties and anti-breast cancer activity[1]. Enterolactone is a radiosensitizer for human breast cancer cell lines through impaired DNA repair and increased apoptosis[2].

HY-118988

CAY10506	PPAR Apoptosis	Cancer
CAY10506 is a PPARγ ligand that can induce cell death and ROS production in a PPARγ-dependent manner in vitro. CAY10506 exhibits radiosensitizing effects, enhancing γ-radiations-induced apoptosis and caspase-3-mediated poly (ADP-ribose) polymerase (PARP) cleavage. CAY10506 can be used in cancer research .

HY-B1640

Ethacrynic acid 2 Publications Verification Etacrynic acid	Glutathione S-transferase NF-κB Calcium Channel NO Synthase	Inflammation/Immunology Cancer
Ethacrynic acid has anti-inflammatory and anticancer activity. Ethacrynic acid is an orally active diuretic. Ethacrynic acid is an inhibitor of glutathione S-transferase (GSTs) and Wnt signaling pathways. Ethacrynic acid is a radiosensitizer. Ethacrynic acid can inhibit airway smooth muscle (ASM) contraction in mice. Ethacrynic acid can increase the outflow of aqueous humor from the eye for the study of glaucoma .

HY-D0713

7ACC2 5 Publications Verification	Monocarboxylate Transporter Mitochondrial Metabolism	Cancer
7ACC2 is a potent monocarboxylate transporter (MCT) inhibitor with an IC₅₀ of 11 nM for inhibition of [ ¹⁴C]-lactate influx. 7ACC2 is also a potent inhibitor of mitochondrial pyruvate transport. 7ACC2 is an anticancer agent through inhibition of lactate flux .

HY-149556

MTX-241F	EGFR PI3K	Cancer
MTX-241F is a selective small molecule inhibitor targeting EGFR and PI3 kinase family members. MTX-241F is able to penetrate the blood-brain barrier and control tumor growth over the long term. MTX-241F exhibits radiosensitizing activity in patient-derived DIPG neurospheres and may be used in the study of diffuse intrinsic pontine glioma (DIPG) .

HY-134594

SENP1-IN-1	E1/E2/E3 Enzyme	Cancer
SENP1-IN-1 is a specific deSUMOylation protease 1 (SENP1) inhibitor extracted from patent CN110627860, Compound 29. SENP1-IN-1 is developed for tumor radiosensitivity enhancement .

HY-134595

SENP1-IN-2	E1/E2/E3 Enzyme	Cancer
SENP1-IN-2 is a specific deSUMOylation protease 1 (SENP1) inhibitor extracted from patent CN110627860, Compound 30. SENP1-IN-2 is developed for tumor radiosensitivity enhancement .

HY-134596

SENP1-IN-3	E1/E2/E3 Enzyme	Cancer
SENP1-IN-3 is a specific deSUMOylation protease 1 (SENP1) inhibitor extracted from patent CN110627860, Compound 17. SENP1-IN-3 is developed for tumor radiosensitivity enhancement .

HY-134597

SENP1-IN-4	E1/E2/E3 Enzyme	Cancer
SENP1-IN-4 is a specific deSUMOylation protease 1 (SENP1) inhibitor extracted from patent CN110627860, Compound 21. SENP1-IN-4 is developed for tumor radiosensitivity enhancement .

Cat. No.	Product Name

HY-L179

Radiosensitizer Library	41 Compounds compounds
Radiotherapy is a common treatment for various cancers, and more than 50% of cancer patients require radiotherapy during the disease treatment. With advances in radiation technology and a better understanding of tumor biology, the efficacy of radiation therapy has gradually improved, and more and more patients have benefited from it. However, even with the use of advanced radiotherapy techniques, there are still many malignant tumor cells with low sensitivity to radiation, leading to the radiation effect is not ideal. To solve this problem, radiosensitizers have received more and more attention. Radiosensitizer is a kind of drug that can enhance the radiosensitivity of tumor cells and improve the effect of radiotherapy. Radiation sensitizers act in a variety of ways, such as killing hypoxic cells, enhancing DNA damage, inhibiting DNA damage repair, and blocking cell cycle progression, making tumor cells more susceptible to radiation damage and death than surrounding normal cells. MCE designs a unique collection of 41 compounds with definite reported radiosensitization. It can be used for drug combination research in anti-cancer treatment.

Radiosensitizer Library

41 Compounds compounds

Radiotherapy is a common treatment for various cancers, and more than 50% of cancer patients require radiotherapy during the disease treatment. With advances in radiation technology and a better understanding of tumor biology, the efficacy of radiation therapy has gradually improved, and more and more patients have benefited from it. However, even with the use of advanced radiotherapy techniques, there are still many malignant tumor cells with low sensitivity to radiation, leading to the radiation effect is not ideal. To solve this problem, radiosensitizers have received more and more attention. Radiosensitizer is a kind of drug that can enhance the radiosensitivity of tumor cells and improve the effect of radiotherapy. Radiation sensitizers act in a variety of ways, such as killing hypoxic cells, enhancing DNA damage, inhibiting DNA damage repair, and blocking cell cycle progression, making tumor cells more susceptible to radiation damage and death than surrounding normal cells.

MCE designs a unique collection of 41 compounds with definite reported radiosensitization. It can be used for drug combination research in anti-cancer treatment.

Cat. No.	Product Name	Type

HY-W076740

8-Bromoadenine 8-Bromo-9H-purin-6-amine	Gene Sequencing and Synthesis
8-Bromoadenine (8-Bromo-9H-purin-6-amine) is a DNA radiosensitizer that inhibits DNA single-strand break repair in cells. 8-Bromoadenine is a brominated derivative of adenine, and radioactive adenine can be prepared by replacing bromine with deuterium .

Cat. No.	Product Name	Target	Research Area

HY-P3229

SN52 1 Publications Verification	NF-κB	Cancer
SN52 is a potent, competitive, and cell-permeable inhibitor of NF-κB2. SN52 is a variant of the SN50 peptide and inhibits the nuclear translocation of p52-RelB heterodimers. SN52 has a strong radiosensitization effect on prostate cancer cells. SN52 can be used for cancer research .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-B0332

Menadione 10+ Cited Publications Vitamin K3	Quinones Structural Classification Microorganisms Classification of Application Fields Source classification Other Diseases Endogenous metabolite Naphthalene Quinones Disease Research Fields	Endogenous Metabolite
Menadione is a naphthoquinone that is converted into active vitamin K2 in the body. Menadione is a potential anticancer agent and radiosensitizer .

HY-N4164

Schinifoline	Zanthoxylum bungeanum Maxim. Alkaloids Classification of Application Fields Source classification Rutaceae Quinoline Alkaloids Plants Disease Research Fields Cancer	Apoptosis
Schinifoline, a 4-quinolinone derivative isolated from Zanthoxylum schinifolium Sieb, improves radiosensitizing effect, and effects cell cycle and apoptotic-inducing effects in cancer .

HY-108692

Enterolactone	Structural Classification Classification of Application Fields Source classification Lignans Phenylpropanoids Endogenous metabolite Disease Research Fields Cancer	Apoptosis Endogenous Metabolite
Enterolactone is a bioactive phenolic metabolite known as a mammalian lignan derived from dietary lignans. Enterolactone has estrogenic properties and anti-breast cancer activity . Enterolactone is a radiosensitizer for human breast cancer cell lines through impaired DNA repair and increased apoptosis .

Cat. No.	Product Name	Chemical Structure

HY-108692S

Enterolactone-d6
Enterolactone-d₆ is the deuterium labeled Enterolactone. Enterolactone is a bioactive phenolic metabolite known as a mammalian lignan derived from dietary lignans. Enterolactone has estrogenic properties and anti-breast cancer activity[1]. Enterolactone is a radiosensitizer for human breast cancer cell lines through impaired DNA repair and increased apoptosis[2].

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Peptides

Natural
Products

Isotope-Labeled Compounds